Asthma is one of the most common chronic respiratory diseases in industrialized countries, and imposes high social and economic costs. It affects approximately 155 million individuals throughout the world and its reported incidence is increasing dramatically in many developed nations.
Studies on the mechanisms of asthma have been mainly focused on two areas: immunoglobulin E (IgE) and cytokines induced by Th cells. IgE is set apart from the other immunoglobulin isotypes by its very low plasma levels and short half-life. In addition to triggering immediate-hypersensitivity reactions and late-phase responses, there is accumulating evidence that preformed IgE can augment humoral and cellular immune responses to allergens. 5) IgE is believed to be one of the major mediators of the immediate hypersensitivity reactions that underlie atopic conditions such as urticaria, seasonal allergy, asthma and anaphylaxis. 6) IgE blockers have recently been developed and show some promise for the treatment of allergic diseases. 7, 8) The strong association of IgE with atopic diseases, and its documented role in immediate hypersensitivity reactions in the airway, have driven efforts to define the cellular and molecular interactions that regulate its production. Consequently, it has been established that the production of IgE is tightly regulated and involves a complex network of cellular and molecular signals. 5) Immune responses to protein antigens are strongly influenced by the nature of the helper T lymphocyte (Th) subsets participating in the response. Th1 cells, through the production of IFN-g, have been shown to evoke cell-dependent immunity and to inhibit the production of IL-4 by Th2 cells, as well as Th2 cell proliferation in vitro. 9, 10) Th1 cells also promote immunoglobulin class switching to IgG2a. 4) In mice, the Th1 cytokine IFN-g has inhibitory effects on Th2-induced airway eosinophilia and airway hyper-responsiveness (AHR). 11) In contrast, IL-4, secreted by Th2 cells, is the exclusive IgE isotype switching factor; it is responsible for the over-production of IgE, it can promote immunoglobulin class switching to IgG1 and IgE, 4) and it stimulates IgE gene recombination and transcription to IgE mRNA, thereby enhancing IgE production by B cells. 12, 13) It is now well established that asthma is characterized by the production of large quantities of IgE antibodies by B cells and by a decrease of the IFN-g/IL-4 (Th1/Th2) ratio.
These results indicate that attenuation or suppression of asthma might be achieved by targeting IgE over-production and Th2 development 14, 15) or Th2 cytokines. 16) However, many bioactive mediators are released from the effective cells in asthma, and the phase and severity of asthma also differ from patient to patient. Therefore, a single drug with a highly specific pharmacological activity cannot always be therapeutically effective. Further, continuous inhibition of one kind of cytokine may lead to immunosuppression, to exacerbated Th1/Th2 imbalance or to autoimmunity. Thus, medicines with a wider range of activities may be more effective. Gyokuheifusan (GHS; Yu-Ping-Feng-San in Chinese) is a classical formula of traditional Chinese medicine (TCM), and is widely prescribed to treat respiratory tract diseases such as respiratory infection, allergic rhinitis, bronchial asthma, and other such conditions in China, Japan and Korea. In TCM, GHS is believed to increase human vigor and to enhance the protective function of the lungs, defending the body against invasion by external pathogenic influences. 17) In this study, we focused on the immuno-regulatory effects of GHS on the Th1/Th2 balance in ovalbumin (OVA)-induced asthma model mice.
MATERIALS AND METHODS
Animal Experiments BALB/c mice (6 weeks old, female), weighing 15-20 g, were purchased from Sankyo Laboservice Co. (Tokyo, Japan). They were housed in plastic cages with sterilized wood-chip bedding and bred in animal rooms kept at a temperature of 23Ϯ2°C and a relative humidity of 55Ϯ10% under a 12-h light-dark cycle. They had free access to tap water and experimental normal diet (CE-2, CLEA Co., Ltd., Tokyo, Japan). The mice were separated into 3 groups, i.e., normal, disease-control and GHS-treated groups. Animals were treated and/or handled according to the Recommendations for Handling of Laboratory Animals for Biomedical Research, compiled by the Committee on the Safety and Ethical Handling Regulations for Laboratory Animals Experiments, Tokyo University of Science. All experimental procedures mentioned below were conducted in accordance with institutional guidelines for the care and use of laboratory animals in research.
Plant Material and Reagents GHS used in this experiment was a dried brown-yellow powder extract with a slightly bitter-sweet taste and was kindly provided by Iskra Industry Co., Ltd. (Tokyo, Japan). The daily dose of GHS (1.5 g) consisted of the extract of a mixture of the following herbs: Astragalus Root (6 g), Atractylodes Rhizome (2 g), and Saposhnikovia Root (2 g). The extraction method was as follows. Astragalus Root 6 kg, Atractylodes Rhizome 2 kg, Saposhnikovia Root 2 kg were mixed and boiled in 6 times their weight of water at 100°C for 1 h, and then the liquid was centrifuged, filtered and lyophilized. The extract amounted to about 15% of the input herbs. Quantitative analysis of marker compounds of each medicinal herb in GHS powder (calycosin from Astragalus Root, atratylenolide III from Atractylodes Rhizome, and GMV from Saposhnikovia Root) by 3D-HPLC chromatogram has been reported by Makino et al., 18) and the chemical structures of these compounds are shown in Fig. 1 . We found that 0.8-1.5 mg of 4Ј-O-b-D-glucosyl-5-O-methylvisamminol (GMV, C 22 H 28 O 10 ) was present in each 1 g package of GHS powder. All drugs used for treatment were suspended in pure water and given in a volume of 25 ml/kg to mice by gastric gavage, while the same volume of pure water was given to the normal group. OVA was used as an antigen. Al(OH) 3 (13 mg/ml) was purchased from Sigma Chemical Co. The following antibodies were used in this study: anti-mouse IFN-g mAb, biotin-conjugated anti-mouse IFN-g mAb, anti-mouse IL-4 mAb, biotin-conjugated anti-mouse IL-4 mAb, (eBioscience, San Diego, CA: XMG1.2, R4-6A2, 11B11, BVD6-24G2, respectively). Recombinant mouse IFN-g and IL-4 were purchased from eBioscience (14-8311-63 and 14-8041-62). All reagents used in this study were of reagent grade.
Induction of Asthma Model
We used a protocol slightly modified from that described by Ikeda et al. 19) Briefly, the disease-control and GHS-treated groups were sensitized i.p. with 100 ml of OVA solution (0.5 mg/ml in saline) emulsified in 150 ml of Al(OH) 3 at a total dosage of 250 ml. A second sensitization was given 6 d after the initial sensitization. Then, 13, 17 and 21 d later, mice were placed in a glass barrel for 30 min and challenged with inhalation of aerosolized OVA solution (10 mg/ml in saline) for excitation. The aerosol was generated by an Omron device (NE-U22, Omron Co.). Mice in the normal group received i.p. mock sensitization with saline-Al(OH) 3 emulsion and were challenged with an aerosol of saline without OVA.
Evaluation of the OVA-Specific IgE Antibody The serum OVA-specific IgE antibody level was evaluated by passive cutaneous anaphylaxis (PCA) reaction according to Bando et al. 20) and Tang et al. 21) with some modifications. Briefly, 100 ml of OVA solution (0.5 mg/ml in saline) and 150 ml of Al(OH) 3 (13 mg/ml) were mixed and i.v. administered at a total dosage of 250 ml. From the second day on, all the groups were given medicine or water individually. Then five days later, all the mice were killed and the serum was obtained. Sera from animals of each group were pooled. An aliquot of the mixed serum was diluted 10 times with PBS, and 100 ml of the diluted sample was injected intracutaneously into the shaved back of mice, at 2 sites. Two days after sensitization, the PCA reaction was elicited with an intravenous injection of 0.2 ml of PBS containing 0.2 mg OVA and 1 mg Evans Blue dye into the tail. After 30 min, blue spots in the skin were cut out with an 8 mm knife, cut into small pieces, and stored in acetone-saline (7 : 3) overnight. The mixture was centrifuged at 3000 rpm for 10 min, then the upper suspension was collected, and the absorbance at 610 nm was read with spectrophotometer (U-2000, Hitachi).
Assay of Plasma Total IgE According to the procedure described by Watanabe et al., 22) blood was collected from the retro-orbital plexus with glass capillary tubes at 1 h and 24 h post-final inhalation, and the plasma was stored at Ϫ80°C until quantitative analysis. To determine the time-course of changes in total IgE, blood samples were collected every 2 d from day 5 to day 38 after the start of the experiment. The total IgE was measured with an ELISA kit (Bethyl Laboratories, Inc.). The assay sensitivity was 3.9-250 ng/ml, and the samples were appropriately diluted. Splenocyte Preparation and Cytokine Assays Levels of IL-4 and IFN-g produced by splenocytes were measured as described by Wang et al. 23) Briefly, the mice were anaesthetized and their spleens were excised 1 h or 24 h after the final inhalation. The spleen cells (5ϫ10 6 cells/ml) from normal or immunized mice were suspended in a 10% FBS/RPMI1640 culture medium and then cultured in the presence of OVA (1 mg/ml) at 37°C in a CO 2 incubator. The supernatant was collected at 24 h, 48 h and 72 h for measurement of IL-4 and IFN-g. The levels of cytokines (IL-4 and IFN-g) in the culture supernatant were measured with ELISA kits (Pharmingen). For cytokine assays, flat-bottomed 96-well Maxisorp plates were coated with purified capture IL-4 mAb or IFN-g mAb overnight at 4°C. The primary mAbs were discarded and the plates were blocked with blocking buffer (1% BSA in PBS) for 1 h at room temperature. The plates were washed 3 times with wash buffer (0.05% Tween 20 in PBS) and blotted on a paper towel. Appropriately diluted samples or IL-4 and IFN-g standards were added and incubated for 2 h at room temperature. The supernatants were discarded and the wells were washed 5 times with wash buffer. Biotin-labeled IL-4 or IFN-g mAbs were added and incubated for 1 h at room temperature. The supernatant was discarded and the wells were washed 5 times with wash buffer, then Avidin-HRP was added, and the plates were incubated for 30 min at room temperature. The Avidin-HRP solution was collected and tetramethylbenzidine (TMB) substrate solution (Pharmingen, San Diego, CA, U.S.A.) was added after the wells had been washed 5 times with wash buffer. The color was allowed to develop for 10-30 min in the dark before the reaction was quenched with a stop solution (2 M H 2 SO 4 ). The OD values were read at 450 nm and the sample concentrations were determined according to the standard curve. The assay sensitivities were 16-2000 pg/ml (IL-4 system) and 78-5000 pg/ml (IFN-g system).
Statistical Analysis The data were subjected to statistical analysis and results were expressed as meanϮS.D. Significance of differences was determined by use of a two-tailed Student's t-test. A probability value of less than 0.05 was considered to be statistically significant.
RESULTS

Influence of the OVA-Specific IgE
In clinical practice, allergen-specific IgE (as demonstrated by skin testing or in vitro assays) is generally believed to be inextricably associated with the induction of allergic airway symptoms, and is used as a guide for environmental modification and immunotherapy. 24) In this study, the size of the blue spot on the skin was assayed as a measure of OVA-specific IgE. Fig. 2 indicates the results of PCA analysis for OVA-specific IgE production in BALB/c mice. The disease-control group sensitized with OVA showed a significantly increased level compared with the non-sensitized normal group. The increase was significantly inhibited by GHS treatment.
Time-Course of Total IgE
Induced by OVA Time-dependent changes in the total IgE levels are illustrated in Fig. 3 . The total IgE content in OVA-induced asthmatic mice was significantly increased from 20 d after the start of the experiment, reaching a maximum at around 30 d. Thereafter, the level gradually decreased up to 38 d. The values of the normal group were 255 ng/ml on day 8, 257 ng/ml on day 14, 205 ng/ml on day 18, and 278 ng/ml on day 24. The results indicate that BALB/c mice can develop an OVA-induced increase of plasma IgE.
Effects of GHS on the Increase of Total IgE Induced by OVA As shown in Fig. 4 , the level of total IgE was significantly increased in the disease-control group compared with the normal group at 1 h post-final inhalation of OVA. The increase was significantly decreased by GHS treatment. At 24 h post-final inhalation, total IgE in the OVA-treated group remained high, though it was lower than that at 1 h post-final Total IgE in plasma post-final inhalation was assayed every two or three days from the 10 th to 38 th day. The values of the normal group were 255 ng/ml on day 8, 257 ng/ml on day 14, 205 ng/ml on day 18, and 278 ng/ml on day 24. The values represent meansϮS.D. of 5 animals.
inhalation. The increase was also inhibited by GHS treatment. These results indicate that GHS may have an inhibitory effect on the over-production of IgE induced by OVA.
Effect of GHS on Increase of IFN-g g Production Induced by OVA Effect of GHS on the increase of IFN-g production induced by OVA at 1 h-post-final inhalation was shown in Fig. 5 . Production of IFN-g was significantly increased at 1 h post-final inhalation when the splenocytes were stimulated with OVA for 24 h, 48 h or 72 h in all cases, compared with the normal group. Treatment with GHS significantly increased the production of IFN-g to a much higher level than in the OVA alone-treated (disease-control) group at all incubation times, indicating that GHS could stimulate Th1 cells and promote IFN-g production at an early time post-inhalation. However, there was no significant increase in the IFN-g production at 24 h post-inhalation (data not shown).
Effect of GHS on IL-4 Production by OVA at 24 h PostInhalation BALB/c mice can develop an IL-4-dependent asthma. 25) In the present study, a significant increase of IL-4 production was obtained when splenocytes were stimulated with OVA for 72 h at 24 h post-final inhalation as shown in Fig. 6 . GHS significantly suppressed the increase of IL-4 production induced by OVA treatment. However, there was no significant increase at 1 h post-final inhalation for any stimulation time examined (data not shown). These results indicate that GHS may inhibit asthma development via upregulation of IFN-g production.
DISCUSSION
Experimental mouse models of allergic asthma established almost 10 years ago have provided new opportunities to study the disease pathogenesis and to develop new therapeutics. Though mouse models do not always reproduce all the features of human disease, wild-type mice develop a clinical syndrome that closely resembles allergic asthma, characterized by eosinophilic lung inflammation, AHR, increased IgE, mucus hypersecretion, and eventually, airway remodeling. Although the mouse models are not exact replicas of the human disease, observations in these models of allergic asthma support many existing paradigms. 26) Further, the models are still considered useful for testing new treatments for allergic asthma.
It has been demonstrated that the Th1/Th2 cell response is shifted to a predominantly Th1 cell response during autoimmune diseases, while an overwhelming Th2 response elicits allergic disorders. 27) Investigations on the balance of Th1/Th2 cytokines production should be helpful to understand the outcomes of different immune responses, and are clinically useful in treating immunologically dysregulated states. 28) GHS, originally described in the book "Experiences of The mice were anaesthetized and their spleens were excised 1 h after the final inhalation. The spleen cells (5ϫ10 6 cells/ml) from normal or immunized mice were suspended in a 10% FBS/RPMI1640 culture medium and then cultured in the presence of OVA (1 mg/ml) at 37°C in a CO 2 incubator. The supernatant was collected at 24 h, 48 h and 72 h for measurement of IFN-g. The values represent meansϮS.D. of 8 animals. Significant differences from the normal group are indicated with ### (pϽ0.001), and from the disease control group with * * * (pϽ0.001) and * * (pϽ0.01). The values of normal group at 1 h and 24 h post inhalation were both below the minimum value of the standard curve. Here, the standard deviation was just delineated at each time point. Significant differences from the normal group are indicated with ### (pϽ0.001), and from the disease control group with * * (pϽ0.01) and * (pϽ0.05).
Zhu Danxi" (written by Zhu Danxi, a famous doctor of the Yuan Dynasty in China), has been clinically prescribed for hundreds of years to treat respiratory tract diseases such as winter colds, respiratory infection, allergic rhinitis, and bronchial asthma. Our previous studies showed that GHS could significantly enhance the survival times of Weiqi immunodeficient mice; it also enhanced the cold-adaptability of immunologically defective mice. 29) We also demonstrated that GHS had preventive and curative effects on acute bacterial rhinitis, and could alleviate the inflammatory reaction and tissue injury induced by acute bacterial inflammation (data not shown; to be published elsewhere).
In this study, we demonstrated that GHS down-regulates the over-production of IgE and IL-4 via a significant and persistent increase of IFN-g. Yang et al. 30) found that Astragalus Root (a main material of GHS) reduced the secretion of IL-4 by regulating the shift of Th1 to Th2, and the total IgE produced by B cells decreased accordingly. Zhao et al. 31) also reported that Astragalus Root can significantly promote IFNg, IgG1, IgG2 and IgG3 production from peripheral blood monocyte (PBMC) in vitro, but had no significant effect on the production of IL-4 or IgG4, suggesting that it can modulate Th1/Th2 function and enhance the immuno-function of asthma sufferers by improving Th1-deficiency. GHS is commonly used to treat respiratory diseases in clinical practice in oriental countries, and there is currently much interest in the mechanisms of its effects on the immune system. An understanding of these may provide a pharmacological basis for more effective clinical application of GHS.
